Eliza Ward: Good morning. Before anything else — Mounjaro got an FDA approval yesterday. August 28th.
Brian Reed: For what? It already has a diabetes label.
Eliza Ward: Right, that's the thing — it still does. But Eli Lilly just expanded it. The new indication is cardiovascular risk reduction. Reducing the risk of cardiovascular death, non-fatal heart attack, non-fatal stroke. In adults with type 2 diabetes at high cardiovascular risk.
Brian Reed: So the drug that launched in 2022 to help with blood sugar is now — on paper at least — a heart drug too.
Eliza Ward: On paper. And Lilly is framing it as a landmark — first dual GIP/GLP-1 receptor agonist to clear an FDA cardiovascular indication. The trial they used was SURPASS-CVOT, five years, Phase 3.
Brian Reed: Five years is — I mean, that's a serious investment to get to this label. What was it comparing tirzepatide against? Placebo?
Eliza Ward: No — and that's the part I want to sit with. Not placebo. The comparator was dulaglutide, which is Trulicity. Another Lilly drug, actually. And the results are — we need to look at them carefully before we say what this approval really means.
Brian Reed: And that's the part that — look, the headline I'm seeing says 'cardiovascular breakthrough,' but the trial didn't beat placebo. It matched Trulicity. Dulaglutide. Which already has a cardiovascular indication.
Eliza Ward: Right — so the bar wasn't standard care. The bar was a drug that already cleared a cardiovascular bar.
Brian Reed: It's like — okay, here's the plain version. It's like a new running shoe brand proving their shoes are at least as fast as a brand that already won a race. That's real. But it's not the same as being the fastest shoe ever tested.
Eliza Ward: That's exactly the structure. And the numbers bear it out — 12.2% of tirzepatide patients hit a major cardiovascular event versus 13.1% on dulaglutide. Hazard ratio 0.92. Less than a percentage point difference in absolute terms. And it was non-inferiority, not superiority.
Brian Reed: Non-inferiority. So — wait, where does the 16 to 23 percent risk reduction come from? Because that number is everywhere in the coverage and it doesn't match what I'm reading in the trial data.
Eliza Ward: Yeah, that's — I mean, I can't find it in the SURPASS-CVOT primary endpoint either. The primary endpoint shows roughly an 8% relative reduction versus dulaglutide. So that 16-23 figure, wherever it's coming from, it's not the headline result of this trial.
Brian Reed: That gap is doing a lot of work in how this gets reported.
Eliza Ward: It is. And — okay, to be fair, non-inferiority still clears a real FDA bar. The P-value was 0.003. The agency looked at this and said it counts. But there's a difference between 'FDA cleared' and 'cardiovascular breakthrough,' and the framing in most headlines doesn't draw that line.
Brian Reed: So the confirmed thing is: Mounjaro matched a drug that already had the cardiovascular credential. The headline version — breakthrough, historic, first of its kind — that's the GIP/GLP-1 novelty framing. And we don't yet know if that dual mechanism is actually doing something different, or if it's just weight loss and glucose control downstream.
Eliza Ward: And that's exactly the take I want to push on — because Lilly's framing keeps landing on the dual GIP/GLP-1 mechanism as the thing that makes this different. The novel engine. But SURPASS-CVOT can't actually show you that. Both arms got active GLP-1 therapy. Tirzepatide on one side, dulaglutide on the other. There's no placebo arm, no untreated group — so there's no way to look at that hazard ratio and say the dual mechanism is what moved it versus just... being on an effective diabetes drug.
Brian Reed: Wait — so the trial design itself makes the mechanism claim unprovable?
Eliza Ward: From this data, yes. You can't separate the dual receptor action from the weight loss and glycemic improvement that tirzepatide produces downstream. If the benefit is mostly metabolic — better glucose control, significant weight loss — then, I mean, a cheaper drug that got you to the same metabolic place might give you the same cardiovascular curve.
Brian Reed: Which is a pretty uncomfortable sentence for Eli Lilly's marketing team.
Eliza Ward: Right — and look, to be fair, I'm speculating there. We genuinely don't know. That's the honest answer.
Brian Reed: The competitive piece makes this sharper, though. Wegovy — semaglutide, Novo Nordisk — got its own cardiovascular indication from the FDA in 2024. But for overweight or obese adults without diabetes. So on paper Lilly and Novo Nordisk are now in different lanes. Different populations. But the mechanistic question still hangs over both of them. Neither trial actually isolates the receptor-level action from the metabolic benefit.
Eliza Ward: Different lanes on paper is — actually, no, that's the right framing. The indications don't overlap cleanly. But the underlying ambiguity is the same for both drugs.
Brian Reed: The part that I think gets more uncomfortable — and this is where I want to come back — is whether any of this actually changes what a payer covers, given that Trulicity already holds an equivalent indication at presumably lower cost. That's the question that hasn't been answered yet.
Eliza Ward: Yeah. The label is real. Whether it moves coverage is a different thing entirely.
Brian Reed: And that gap — label existing versus coverage actually changing — let me make it concrete. Patient with type 2 diabetes, established atherosclerotic cardiovascular disease. Her cardiologist sees the August 28 approval and reaches for Mounjaro. New cardiovascular label, dual mechanism, the whole story. She files for prior authorization. And her insurer looks at SURPASS-CVOT and says — wait, this matched dulaglutide. Trulicity. Which we already cover. And which costs less.
Eliza Ward: That's the exact scenario where the label doesn't move anything.
Brian Reed: Right. And the cost-effectiveness math — payers use number-needed-to-treat for this. How many patients have to take the drug to prevent one cardiovascular event. That number isn't in the SURPASS-CVOT sources I've seen. So the insurer is looking at equivalent outcomes, an older cheaper comparator, and no NNT figure to justify the premium.
Eliza Ward: Wait — the NNT's just absent? From what's publicly available?
Brian Reed: From what's in the sources, yeah. And that absence is itself — I mean, that's not a small thing. That's the number a pharmacy benefit manager puts in a spreadsheet.
Eliza Ward: Okay but — Lilly's installed base is real. Mounjaro is the number one most-prescribed branded type 2 diabetes drug in the U.S. right now. That's not nothing. Prescribers are already in the habit. So the question is whether the payer tier moves, not whether doctors switch.
Brian Reed: Being the most-prescribed drug doesn't protect you from step therapy. Actually — that's the uncomfortable part. Payers can look at that installed base and say, step through dulaglutide first. Prove it doesn't work. Then we'll cover Mounjaro. Which is exactly the off-label coverage denial pattern we've already seen play out across the GLP-1 class.
Eliza Ward: Ozempic, Wegovy — yeah, prior auth denials on those are documented. So the pattern exists. The concrete thing to watch is whether United, Aetna — any major payer — actually revises its tirzepatide tier in the months after August 28. That's the signal. Not the label. The formulary.
Brian Reed: And if they tier tirzepatide behind dulaglutide, then for that patient with established cardiovascular disease — the cardiovascular label exists. Her cardiologist has it. And it still doesn't get her the drug.
Eliza Ward: And that's — I mean, that's where the August 28 date actually matters. The FDA did something real. The label changed. Eli Lilly has what it wanted from a regulatory standpoint. That part is settled. The open question is whether that label travels the last mile — whether it reaches the patient whose insurer is looking at SURPASS-CVOT and seeing dulaglutide as equivalent and cheaper. Those are two completely different outcomes sitting inside the same approval.
Brian Reed: Right — and we don't have a documented case yet of a major payer revising tirzepatide's formulary tier in response to this. That's the thing that would actually tell us which outcome we're in.
Eliza Ward: No, we don't. So watch the formulary updates. United, Aetna — any tier revision after August 28 is the signal. Not the label.
Brian Reed: Yeah. The story isn't over.
